Ateganosine (THIO)
Non-Small Cell Lung Cancer (NSCLC)
Key Facts
About MAIA Biotechnology
MAIA Biotechnology is a targeted therapy and immuno-oncology company focused on developing first-in-class drugs with novel mechanisms of action to improve and extend the lives of cancer patients. Its core achievement is the advancement of its lead asset, ateganosine (THIO), a dual-mechanism telomere-targeting agent, into Phase 2 clinical trials. The company's strategy leverages a proprietary platform of telomere biology to induce direct cancer cell death and generate an immunogenic response, differentiating it from conventional therapies. MAIA operates as a public entity, trading on the NYSE American exchange, and is positioned within the high-potential RNA & Gene Therapy sector.
View full company profileAbout MAIA Biotechnology
MAIA Biotechnology is a targeted therapy and immuno-oncology company focused on developing first-in-class drugs with novel mechanisms of action to improve and extend the lives of cancer patients. Its core achievement is the advancement of its lead asset, ateganosine (THIO), a dual-mechanism telomere-targeting agent, into Phase 2 clinical trials. The company's strategy leverages a proprietary platform of telomere biology to induce direct cancer cell death and generate an immunogenic response, differentiating it from conventional therapies. MAIA operates as a public entity, trading on the NYSE American exchange, and is positioned within the high-potential RNA & Gene Therapy sector.
View full company profileTherapeutic Areas
Other Non-Small Cell Lung Cancer (NSCLC) Drugs
| Drug | Company | Phase |
|---|---|---|
| LW-02 Immunopheresis | Immunicom | Phase 2 |
| Idylla EGFR Mutation Assay | Biocartis | Approved |
| ABD-3001 | Advanced Biodesign | Phase 1 |
| Macrocyclic OMNI-EGFR Inhibitor | BlossomHill Therapeutics | Phase 1 |
| TUMORIN Clinical Trial | Nilogen Oncosystems | N/A (Diagnostic Validation) |
| Membrex™ | Metaclipse Therapeutics | Pre-clinical |
| Lazertinib (Leclaza) | Genosco | Approved |
| IPH5201 (anti-CD39 mAb) | Orega Biotech | Phase 2 |
| Platin-DRP® | Chosa Oncology | Validation |
| Undisclosed RNA Immunotherapy | Epitopea | Pre-clinical |
| Aspyre Clinical Test for Lung | Biofidelity | Commercial |
| EGFR Mutation Detection Assay | Stilla Technologies | Assay Development/Validation |